Infliximab

Main Page

Contact

Infliximab [Turkderm-Turk Arch Dermatol Venereol]

Turkderm-Turk Arch Dermatol Venereol. 2022; 56(1): 37-40 | DOI: 10.4274/turkderm.galenos.2022.54782

Infliximab

�lgen Ertam Sa�duyu
Ege University Faculty of Medicine, Department of Dermatology and Venereology, �zmir, Turkey

Infliximab is a TNF-α inhibitor in the form of a chimeric monoclonal antibody. It received FDA approval in 2006 for the treatment of adult patients with severe chronic plaque psoriasis who developed side effects with conventional therapies or in whom these therapies were contraindicated or did not produce any response. Infliximab is administered via intravenous infusion, and infusion reactions are one of its common side effects. It is not suitable for intermittent treatment due to the high risk of infusion reaction, risk of developing antibodies, and loss of efficacy. Infliximab has the advantage of showing rapid clinical response in the treatment of unstable psoriasis and generalized pustular psoriasis.

Keywords: Infliximab, TNF-α,, psoriasis

�nfliksimab

�lgen Ertam Sa�duyu
Ege �niversitesi T�p Fakültesi, Deri ve Zührevi Hastal�klar Anabilim Dal�, �zmir

�nfliksimab, TNF-α inhibit�r� olan �imerik bir monoklonal antikordur. Konvansiyonel tedavilerle yan etki geli�mi�, kontrendikasyon bulunan veya yan�ts�z �iddetli kronik plak psoriasisi olan eri�kin hastalar�n tedavisinde 2006 y�l�nda FDA onay� alm��t�r. �nfliksimab intraven�z inf�zyon yoluyla uygulanmaktad�r ve inf�zyon reaksiyonlar� s�k g�r�len bir yan etkisidir. Artm�� inf�zyon reaksiyon riski, antikor geli�im riski ve etkinlik kayb� nedeniyle aral�kl� tedavi i�in uygun de�ildir. �nfliksimab, stabil olmayan psoriasis ve generalize p�st�ler psoriasis tedavisinde h�zl� klinik yan�t avantaj�na sahiptir.

Anahtar Kelimeler: �nfliksimab, TNF-α,, psoriasis

�lgen Ertam Sa�duyu. Infliximab. Turkderm-Turk Arch Dermatol Venereol. 2022; 56(1): 37-40

Corresponding Author: �lgen Ertam Sa�duyu, T�rkiye

TOOLS